AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

North Chicago officials, in a statement, said the 11,365-square-foot center will include a convenience store, video gaming lounge, drivers’ lounge with couches and showers, a full-service restaurant, ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 results, which, according to BNP Paribas, were driven by its older blockbuster ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. AbbVie (NYSE:ABBV) has agreed to acquire Capstan ...

The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...

MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US MedImpact Holdings, Inc. today announced the ...

AbbVie (ABBV) posted better-than-expected financials for Q4 2025 as the company’s former best seller, Humira, exceeded Street forecasts, offsetting a mixed performance from its newer immunology drugs, ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk), ...

AbbVie expects $31.6 billion from Rinvoq, Skyrizi in 2026 Shares fall 6% after Rinvoq's Q4 sales miss Skyrizi sales surpass expectations with $5.01 billion Feb 4 (Reuters) - AbbVie (ABBV.N), opens new ...